Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison
Koo Wilson, Francesca Chiodi, Abby Paine, Zalmai Hakimi, Victoria Ward, Tom Macmillan, Daniel Eriksson, Silvia Mappa
Springer Nature ·
2025-03-28
· DOI 10.1007/s12325-025-03169-9
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Koo Wilson, Francesca Chiodi, Abby Paine, Zalmai Hakimi, Victoria Ward, Tom Macmillan et al. Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison. // Advances in Therapy. – 2025. – DOI: 10.1007/s12325-025-03169-9. – URL: https://doi.org/10.1007/s12325-025-03169-9
Koo Wilson, Francesca Chiodi, Abby Paine, Zalmai Hakimi, Victoria Ward, Tom Macmillan, Daniel Eriksson, & Silvia Mappa (2025). Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison. Advances in Therapy. https://doi.org/10.1007/s12325-025-03169-9
Koo Wilson, et al. “Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison.” Advances in Therapy, 2025. doi:10.1007/s12325-025-03169-9.
@article{Wilson2025,
title = {Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison},
author = {Wilson, Koo and Chiodi, Francesca and Paine, Abby and Hakimi, Zalmai and Ward, Victoria and Macmillan, Tom and Eriksson, Daniel and Mappa, Silvia},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03169-9},
url = {https://doi.org/10.1007/s12325-025-03169-9}
}